AstraZeneca Presents Data At ASN Kidney Week 2022 Reinforcing Urgent Need For Early Screening Of Chronic Kidney Disease And The Benefits Of Earlier Treatment Initiation For Patients And Healthcare Systems
November 07, 2022
November 07, 2022
WILMINGTON, Delaware, Nov. 7 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca, a leader in cardiorenal research, presented new data at the American Society of Nephrology (ASN) Kidney Week 2022 in Orlando, Florida, US on the importance of earlier screening and diagnosis of chronic kidney disease (CKD) and the impact of FARXIGA(R) (dapagliflozin) on reducing healthcare costs./1,/2 These findings were also simultaneously published in . . .
AstraZeneca, a leader in cardiorenal research, presented new data at the American Society of Nephrology (ASN) Kidney Week 2022 in Orlando, Florida, US on the importance of earlier screening and diagnosis of chronic kidney disease (CKD) and the impact of FARXIGA(R) (dapagliflozin) on reducing healthcare costs./1,/2 These findings were also simultaneously published in . . .